Odyssey Therapeutics: presents Phase 2a OD-001 induction results

What happened On Oct 20, 2026, Odyssey Therapeutics, Inc. announced that it issued a press release titled "Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026" and posted a corporate presentation on its website at https://investors.odysseytx.com/news-events/presentations. The press release and presentation were furnished with the Current Report on Form 8-K as Exhibit 99.1 and Exhibit 99.2.

Key details

• Date of filing and disclosures: Oct 20, 2026.
• Press release title: "Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026."
• Presentation location: posted on the company's investor presentations page at the above URL.
• Exhibits filed with the Form 8-K: Exhibit 99.1 (press release) and Exhibit 99.2 (corporate presentation).
• Form 8-K signed by Jason Haas, Chief Financial Officer, on Oct 20, 2026.

Why it may matter The filing reports Item 7.01, Regulation FD disclosure, which covers public release of material information via a press release and presentation. The filing also includes exhibits under Item 9.01. This filing does not show why the company acted.